A detailed history of Farther Finance Advisors, LLC transactions in Argenx Se stock. As of the latest transaction made, Farther Finance Advisors, LLC holds 55 shares of ARGX stock, worth $31,032. This represents 0.0% of its overall portfolio holdings.

Number of Shares
55
Previous 61 9.84%
Holding current value
$31,032
Previous $26.5 Million 12.56%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$434.22 - $551.9 $2,605 - $3,311
-6 Reduced 9.84%
55 $29.8 Million
Q2 2024

Jul 31, 2024

BUY
$356.01 - $451.55 $356 - $451
1 Added 1.67%
61 $26.5 Million
Q1 2024

May 13, 2024

BUY
$356.95 - $413.29 $1,427 - $1,653
4 Added 7.14%
60 $23.8 Million
Q4 2023

Feb 14, 2024

BUY
$338.91 - $506.01 $18,640 - $27,830
55 Added 5500.0%
56 $21.3 Million
Q3 2023

Nov 13, 2023

BUY
$369.35 - $548.43 $369 - $548
1 New
1 $492,000
Q4 2022

Sep 11, 2023

BUY
$342.17 - $402.31 $684 - $804
2 New
2 $758,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $31.2B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Farther Finance Advisors, LLC Portfolio

Follow Farther Finance Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Farther Finance Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Farther Finance Advisors, LLC with notifications on news.